Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
62.33
+5.21 (9.12%)
At close: Jan 16, 2026, 4:00 PM EST
62.79
+0.46 (0.74%)
After-hours: Jan 16, 2026, 7:59 PM EST
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$640,996
Profits / Employee
$210,765
Market Cap
268.23B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NVO News
- 1 day ago - Trump's Greenland ambition: stocks that may face tariff shock in 2026 - Invezz
- 1 day ago - Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data - Benzinga
- 1 day ago - Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid' launch - CNBC
- 1 day ago - Novo Nordisk's Wegovy Weight Loss Shot Approved At Higher Dose in U.K. - WSJ
- 1 day ago - Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch - Reuters
- 1 day ago - Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss - Barrons
- 1 day ago - Novo shares jump 7% ahead of US prescription data for Wegovy pill - Reuters
- 3 days ago - Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference - CNBC